Loading clinical trials...

Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine Safety and Pharmacokinetics of Exenatide Long-Acting Release Administered Weekly in Subjects With Type 2 Diabetes Mellitus

NCT00103935•AstraZeneca

View on ClinicalTrials.gov

Summary

Exenatide LAR is a long-acting release formulation of exenatide, which is a twice-daily dosage form currently under investigation as a potential treatment for people with type 2 diabetes mellitus. This study will assess the safety, tolerability, and pharmacokinetics of Exenatide LAR administered weekly by subcutaneous injection in people with type 2 diabetes mellitus.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Has type 2 diabetes treated with either: \*A stable regimen of metformin for a minimum of 3 months, and/or \*Diet modification and exercise for a minimum of 3 months.
•Has HbA1c of 7.1% to 11.0%, inclusive.
•Has a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive.

Exclusion Criteria

•Received any investigational drug within 3 months prior to screening.
•Is currently treated with any of the following excluded medications: \*Thiazolidinediones within 3 months of screening; \* Sulfonylureas within 3 months of screening; \* Insulin within 1 year of screening.
•Participated previously in an exenatide clinical study.

Locations (7)

Research Site

Walnut Creek, California, United States

Research Site

Honolulu, Hawaii, United States

Research Site

St Louis, Missouri, United States

Research Site

Butte, Montana, United States

Research Site

Portland, Oregon, United States

Research Site

San Antonio, Texas, United States

Research Site

Olympia, Washington, United States

Key Dates

Start Date

February 1, 2005

Primary Completion Date

October 1, 2005

Completion Date

October 1, 2005

Last Updated

February 24, 2015

Enrollment

ACTUAL participants

Conditions

Type 2 Diabetes Mellitus

Interventions

placebo

DRUG

placebo

DRUG

Exenatide LAR

DRUG

Exenatide LAR

DRUG

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITINGNA

Achieving Routine Intervention and Screening for Emotional Health

NCT06887049

Type 2 Diabetes Mellitus (T2DM)Diabetes Distress

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 24, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Achieving Routine Intervention and Screening for Emotional Health

A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With Type 2 Diabetes Mellitus

Human Immunodeficiency Virus (HIV) Food Insecurities

Impact of the New Generation Anti-diabetic Drugs on Diabetic Retinopathy

Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease